

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, SINGAPORE, HONG KONG, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE NOTE THE IMPORTANT INFORMATION IN THE END OF THE PRESS RELEASE

Xbrane Biopharma publishes a prospectus for admission to trading of shares on Nasdaq Stockholm in connection with a directed share issues completed on November 11 2020

The Board of Directors of Xbrane Biopharma AB (publ) ("Xbrane Biopharma" or the "Company") resolved on 11 November 2020 to carry out a directed issue of 2,919,708 shares at a subscription price of 68.50 SEK per share, corresponding to approximately SEK 200 million before deduction of costs related to the transaction (the "Directed Share Issue"). The Board of Directors in Xbrane Biopharma has, in connection with the admission to trading of shares on Nasdaq Stockholm issued in the Directed Share Issue, on voluntary basis prepared a prospectus which today has been approved and registered with the Swedish Financial Supervisory Authority (Sw. Finansinspektionen). The prospectus is available on the Company's website, <https://xbrane.com/sv/investors/>.

Publication of prospectus

Xbrane Biopharma has on voluntary basis prepared a prospectus in connection with that the shares from the Directed Share Issue are admitted to trading on Nasdaq Stockholm. The shares in the Directed Share Issue is estimated to be registered with Euroclear Sweden AB today, 16 November 2020. For complete information about the Directed Share Issue and the admission to trading of the shares on Nasdaq Stockholm, refer to the Company's press releases published on 11 November 2020 and to the prospectus which has been prepared by the Company and today has been approved and registered with the Swedish Financial Supervisory Authority. The prospectus is available on the Company's website (<https://xbrane.com/sv/investors/>) and will be available on the Swedish Financial Supervisory Authority's website (<https://fi.se/sv/vara-register/prospektregistret/>).

Advisers

Baker McKenzie Advokatbyrå KB is acting as legal adviser to the Company.

Responsible persons

The information was provided by the responsible person below for publication at the point in time specified by Xbrane Biopharma's news distributor MFN at the publication of this press release. The person below may be contacted for further information.

Contacts

Martin Åmark, CEO/IR
M: +46 (0) 763-093 777
E: martin.amark@xbrane.com

About Xbrane Biopharma

Xbrane Biopharma AB develops biological drugs based on a platform technology that provides significantly lower production costs compared to competing systems. Xbrane Biopharma's leading product Xlucane, a Lucentis® biosimilar candidate, addresses the €10.4b ophthalmic VEGFa inhibitor market. Xlucane is in phase III and marketing authorization is expected mid-2022. Xbrane Biopharma has additionally four biosimilars in its pipeline targeting €8.7b in originator sales. Xbrane Biopharma's head office is in Solna, just outside Stockholm. Xbrane Biopharma is listed on Nasdaq Stockholm under the ticker XBRANE. For more information, visit www.xbrane.com.

Important information

The release, announcement or distribution of this press release may, in certain jurisdictions, be subject to restrictions. The recipients of this press release in jurisdictions where this press release has been published or distributed shall inform themselves of and follow such restrictions. The recipient of this press release is responsible for using this press release, and the information contained herein, in accordance with applicable rules in each jurisdiction. This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in Xbrane Biopharma in any jurisdiction, neither from Xbrane Biopharma nor from someone else.

This announcement does not identify or suggest, or purport to identify or suggest, the risks (direct or indirect) that may be associated with an investment in the new shares.

This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the US Securities Act of 1933, as amended (the "**Securities Act**"), and may not be offered or sold within the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offering of the securities in the United States. The information in this press release may not be announced, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, within or into Australia, Hong Kong, Japan, Canada, New Zealand, Singapore, South Africa, the United States or in any other jurisdiction where such announcement, publication or distribution of the information would not comply with applicable laws and regulations or where such actions are subject to legal restrictions or would require additional registration or other measures than what is required under Swedish law. Actions taken in violation of this instruction may constitute a crime against applicable securities laws and regulations.

This press release is not a prospectus for the purposes of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 (the "**Prospectus Regulation**") and has not been approved by any regulatory authority in any jurisdiction. Xbrane Biopharma has not authorized any offer to the public of shares or rights in any member state of the EEA and no prospectus for an offering has been or will be prepared in connection with the Directed Share Issue. In any EEA Member State, this communication is only addressed to and is only directed at qualified investors in that Member State within the meaning of the Prospectus Regulation.

In the United Kingdom, this document and any other materials in relation to the securities described herein is only being distributed to, and is only directed at, and any investment or investment activity to which this document relates is available only to, and will be engaged in only with, "qualified investors" who are (i) persons having professional experience in matters relating to investments who fall within the definition of "investment professionals" in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"); or (ii) high net worth entities falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as "relevant persons"). In the United Kingdom, any investment or investment activity to which this communication relates is available only to, and will be engaged in only with, relevant persons. Persons who are not relevant persons should not take any action on the basis of this press release and should not act or rely on it.

Forward-looking statements

This press release contains forward-looking statements that reflect the Company's intentions, beliefs, or current expectations about and targets for the Company's future results of operations, financial condition, liquidity, performance, prospects, anticipated growth, strategies and opportunities and the markets in which the Company operates. Forward-looking statements are statements that are not historical facts and may be identified by words such as "believe", "expect", "anticipate", "intend", "may", "plan", "estimate", "will", "should", "could", "aim" or "might", or, in each case, their negative, or similar expressions. The forward-looking statements in this press release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, it can give no assurances that they will materialize or prove to be correct. Because these statements are based on assumptions or estimates and are subject to risks and uncertainties, the actual results or outcome could differ materially from those set out in the forward-looking statements as a result of many factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements. The Company does not guarantee that the assumptions underlying the forward-looking statements in this press release are free from errors and readers of this press release should not place undue reliance on the forward-looking statements in this press release. The information, opinions and forward-looking statements that are expressly or implicitly contained herein speak only as of its date and are subject to change without notice. Neither the Company nor anyone else undertake to review, update, confirm or to release publicly any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this press release, unless it is not required by law or Nasdaq Stockholm's rule book for issuers.

Press Release
16 November 2020 15:50:00 CET



Attachments

[Xbrane Biopharma publishes a prospectus for admission to trading of shares on Nasdaq Stockholm in connection with a directed share issues completed on November 11 2020](#)